Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quandary Remains In Creating Abuse-Resistant Opioid Painkillers

Executive Summary

FDA's advisory committees honed in on the inherent paradox in the regulation of abuse-resistant opioid painkillers - that it is impossible to fully prove an abuse-deterrent effect without approving a product and seeing how it works on the market - at the April 22 review of King/Acura's Acurox

You may also be interested in...

Alkermes' Vivitrol For Opioid Dependence Could Be Dealt Wild Card At Advisory Committee

Expert panels have recently shown they may think differently from FDA on the subject of opioids..

FDA Finalizing Opioid REMS Proposal, Sets Joint Advisory Committee Meeting For July

FDA wants to gather feedback from advisors and from the public on the classwide REMS for opioid analgesics, and judging from the stakeholder meetings the agency has held so far, it will get an earful.

King Aims To File New Acurox NDA In Early 2011

King Pharmaceuticals expects to file a new drug application in early 2011 for its pain drug Acurox, excluding niacin as a potential abuse deterrent, execs told investors during a first quarter earnings call May 5

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts